Clinical Trial: Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A Pilot Study

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07916922) titled 'Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A Pilot Study' on Oct. 15.

Brief Summary: This study is designed as a pilot randomized controlled trial to investigate the potential role of trimetazidine (TMZ) as an adjuvant therapy in patients with acute Aluminum phosphide poisoning.

Study Start Date: May 05

Study Type: INTERVENTIONAL

Condition: Aluminum Phosphide Poisoning

Intervention: DRUG: Trimetazidine

Trimetazidine (TMZ), Vastarel (R) MR 35mg tablets, Servier, France, was purchased from a local pharmacy in Egypt and dissolved in 60ml L...